KURA: Kura Oncology, Inc. Company Profile & Statistics

Kura Oncology, Inc. Profile

About

Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL, ERK inhibitor program and Menin MLL inhibitor program. Kura Oncology, Inc. is headquartered in La Jolla, California.

Info & Links

CEO

Troy E. Wilson

Headquarters

12730 HIGH BLUFF DRIVE, SUITE 400
SAN DIEGO, CA 92130, UNITED STATES

Auditor

Ernst & Young LLP

Share holders

Employees

192

Kura Oncology, Inc. Statistics

Valuation Measures

Market Capitalization²

889.75M

Enterprise Value

804.14M

Enterprise Value/EBITDA(ttm)

-2.66

Price to Earnings Ratio(ttm)

Price to Sales(ttm)

8.98

Price to Book(mrq)

3.84

Price to Cash(ytd)

Profitability

Gross Margin(ttm)

75.00%

Operating Margin(ttm)

-208.48%

Profit Margin(ttm)

-299.19%

Return on Equity(ttm)

-65.42%

Return on Invested Capital(ttm)

-71.10%

Return on Assets(ttm)

-30.59%

Income Statement

Revenue(ttm)

50.15M

Revenue Per Share(ttm)

0.58

Gross Profit(ttm)

50.15M

EBITDA(ttm)³

-302.86M

Net Income Available to Common(ttm)

-216.88M

Diluted EPS(ttm)

-2.48

Share Statistics

Beta (5Y Monthly)

0.21

52-Week Change

0.23%

S&P 500 52-Week Change

12.83%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding¹

87.02M

Dividend Yield

0.00%

Float⁴

81.45M

% Held by Insiders

6.40%

% Held by Institutions

Balance Sheet

Total Cash(mrq)

549.66M

Total Cash Per Share(mrq)

6.32

Total Debt(mrq)

9.67M

Total Debt/Equity(mrq)

3.99%

Current Ratio(mrq)

5.12%

Quick Ratio(mrq)

5.12%

Book Value Per Share(mrq)

2.79

Cash Flow

Operating Cash Flow Per Share(ytd)

-2.07

Free Cash Flow(ytd)

-185.65M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

KURA

Kura Oncology, Inc.